ReviewMolecular diagnosis & therapy2025
Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine.
Review in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Gastric cancer organoids: a promising model for personalized treatment of gastric cancer.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer is a highly heterogeneous disease, with substantial variations observed among patients in clinical manifestation, histological characteristics, and drug sensitivities. Achieving precision medicine necessitates a comprehensive understanding of the molecular mechanisms underlying gastric cancer and the establishment of robust preclinical models. Organoids, cultivated from cancer cells within tumor tissues, utilizing three-dimensional tissue culture techniques, faithfully replicate the features and heterogeneity of in vivo tumors and have emerged as a promising platform. This review explores the application of gastric cancer-derived organoids (GCOs) in preclinical research and clinical translation, highlighting current challenges and outlining future prospects. Although this technology remains some distance from direct clinical application, it holds tremendous potential for clinical utilization.
Indexed as
Identifiers
40906049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.